Prediction of all-cause mortality in haemodialysis patients using a Bayesian network.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
01 08 2020
Historique:
received: 11 07 2019
accepted: 27 11 2019
pubmed: 11 2 2020
medline: 16 12 2020
entrez: 11 2 2020
Statut: ppublish

Résumé

All-cause mortality in haemodialysis (HD) is high, reaching 15.6% in the first year according to the European Renal Association. A new clinical tool to predict all-cause mortality in HD patients is proposed. It uses a post hoc analysis of data from the prospective cohort study Photo-Graph V3. A total of 35 variables related to patient characteristics, laboratory values and treatments were used as predictors of all-cause mortality. The first step was to compare the results obtained using a logistic regression to those obtained by a Bayesian network. The second step aimed to increase the performance of the best prediction model using synthetic data. Finally, a compromise between performance and ergonomics was proposed by reducing the number of variables to be entered in the prediction tool. Among the 9010 HD patients included in the Photo-Graph V3 study, 4915 incident patients with known medical status at 2 years were analysed. All-cause mortality at 2 years was 34.1%. The Bayesian network provided the most reliable prediction. The final optimized models that used 14 variables had areas under the receiver operating characteristic curves of 0.78 ± 0.01, sensitivity of 72 ± 2%, specificity of 69 ± 2%, predictive positive value of 70 ± 1% and negative predictive value of 71 ± 2% for the prediction of all-cause mortality. Using artificial intelligence methods, a new clinical tool to predict all-cause mortality in incident HD patients is proposed. The latter can be used for research purposes before its external validation at: https://www.hed.cc/? a=twoyearsallcausemortalityhemod&n=2-years%20All-cause%20Mortality%20Hemodialysis.neta.

Sections du résumé

BACKGROUND
All-cause mortality in haemodialysis (HD) is high, reaching 15.6% in the first year according to the European Renal Association.
METHODS
A new clinical tool to predict all-cause mortality in HD patients is proposed. It uses a post hoc analysis of data from the prospective cohort study Photo-Graph V3. A total of 35 variables related to patient characteristics, laboratory values and treatments were used as predictors of all-cause mortality. The first step was to compare the results obtained using a logistic regression to those obtained by a Bayesian network. The second step aimed to increase the performance of the best prediction model using synthetic data. Finally, a compromise between performance and ergonomics was proposed by reducing the number of variables to be entered in the prediction tool.
RESULTS
Among the 9010 HD patients included in the Photo-Graph V3 study, 4915 incident patients with known medical status at 2 years were analysed. All-cause mortality at 2 years was 34.1%. The Bayesian network provided the most reliable prediction. The final optimized models that used 14 variables had areas under the receiver operating characteristic curves of 0.78 ± 0.01, sensitivity of 72 ± 2%, specificity of 69 ± 2%, predictive positive value of 70 ± 1% and negative predictive value of 71 ± 2% for the prediction of all-cause mortality.
CONCLUSIONS
Using artificial intelligence methods, a new clinical tool to predict all-cause mortality in incident HD patients is proposed. The latter can be used for research purposes before its external validation at: https://www.hed.cc/? a=twoyearsallcausemortalityhemod&n=2-years%20All-cause%20Mortality%20Hemodialysis.neta.

Identifiants

pubmed: 32040147
pii: 5733036
doi: 10.1093/ndt/gfz295
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1420-1425

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Auteurs

Marleine Mefeugue Siga (MM)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Néphrologie, Université Claude Bernard Lyon 1, Lyon, France.

Michel Ducher (M)

Pharmacie, Hospices Civils de Lyon, EMR3738 Ciblage thérapeutique en oncologie, Université Claude Bernard Lyon 1, Lyon, France.

Nans Florens (N)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Néphrologie, Université Claude Bernard Lyon 1, Lyon, France.

Hubert Roth (H)

Faculté de médecine, Université Grenoble Alpes, Domaine de la merci Place du Commandant Nal, La Tronche, France.

Nadir Mahloul (N)

Campus Sanofi Val de Bièvre, Gentilly, France.

Denis Fouque (D)

Hospices Civils de Lyon, Hôpital Lyon-Sud, Service de Néphrologie, Université Claude Bernard Lyon 1, Pierre Bénite, France.

Jean-Pierre Fauvel (JP)

Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Néphrologie, Université Claude Bernard Lyon 1, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH